Over 200 patients across ION 1&2 were cirrhotics. With ~98% overall SVRs, under the most conservative assumption (100% SVR in non-cirrhotics), SVR in cirrhotics is still 90%. Which is good enough, but it's likely higher. ABBV can message their Turquoise data specifically generated for this population and this may confer a marketing advantage, but I doubt there is a real clinical advantage here.
Market Data 
Markets 
AI
